Single answer
Is Aerovate Therapeutics Inc (AVTE) a buy or sell?
4starter turns market data into one clear verdict you can act on.
Create a free account to save tickers and track your signals.
Log in to turn on watchlist alerts.
Decision snapshot
Everything you need to act fast, in one glance.
What is the conclusion?
Right now our advanced algorithms say:
Do analysts agree?
We compare consensus targets with today's price.
Consensus target for Aerovate Therapeutics Inc is $13.00, which is $10.32 (385.07%) above the current price today's price.
Low target: $2.00 | High target: $35.00
Company snapshot
A quick overview of the business and its public profile.
Aerovate Therapeutics Inc a clinicalstage biopharmaceutical company focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States The company focuses on advancing AV101 a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension which is in Phase 2bPhase 3 trial Aerovate Therapeutics Inc was incorporated in 2018 and is headquartered in Waltham Massachusetts
Website: httpsaerovatetxcom
Rates and inflation backdrop
US inflation for January 2026 was 0.17%. Over the last 12 months, inflation is 2.83%. The 10-year yield is 4.04 and is down -0.110 over the last 30 days.
Inflation sensitivity
Debt ratio: 0.00. Cash flow to debt ratio: -96.50. Net profit margin: -58,265.20%. Inflation risk score: medium (0.70/1).
Dividend history check
We cannot find any recorded dividends paid in our systems.
Trading liquidity
No, the average daily trading liquidity for Aerovate Therapeutics Inc is $654,129. Trading in stocks with this little trading liquidity is very dangerous, and you can get into a situation where it will be hard to trade your stocks. In addition, these types of stocks usually have very high volatility.
10-year return check
We cannot find data for Aerovate Therapeutics Inc 10 years ago, but if you had invested on 2021-06-30 when the price was $22.83, you would have made a profit of $70.97 per share or 310.86%.
Why this answer
We combine price momentum, volatility, and trend signals to simplify the decision to one word.
Signal engine scans price, trend, and momentum indicators.
Targets and sentiment are checked against the live quote.
We keep the output simple: buy, sell, or hold.
Analyst consensus
How Wall Street targets compare to today's price.